Menu

“Minibrains” May Soon Include Neanderthal DNA

Brain organoids engineered to carry the genetic material could reveal how our brains are similar to and different from those of our closest relatives.

May 14, 2018
Ashley Yeager

ISTOCK, HALAMKAHuman stem cells edited to contain Neanderthal DNA will soon be grown into “miniature brains,” The Guardian reports.

“We’re seeing if we can find basic differences in how nerve cells function that may be a basis for why humans seem to be cognitively so special,” Svante Pääbo, who directs the genetics department at the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany, where the experiments are being performed, tells the publication.

Pääbo and his colleagues have already extracted Neanderthal genes for the development of the skull and face and inserted them into mice. They have also extracted genes for pain perception from Neanderthal DNA and edited them into frogs’ genomes to determine whether the pain thresholds between humans and Neanderthals differ, according to The Guardian. Now, the researchers want to do the same with three genes linked to the growth of neurons in organoids.

Neanderthals, recent research revealed, drew cave art, buried their dead, and had bigger brains than humans. So by testing how the Neanderthal genes work in brain organoids, the scientists can determine if connections between nerve cells, electrical activity, and early brain development are similar to modern humans.

“We want to know … is there something hiding there that really sets us apart?” Pääbo says. “Is there a biological basis for why modern humans went on to become millions and eventually billions of people, spread across the world and have culture?”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.